Literature DB >> 19888788

Abdominal aortitis after use of granulocyte colony-stimulating factor.

Giridhar U Adiga1, Dahlia Elkadi, Sandeep K Malik, Jill D Fitzpatrick, Stefan Madajewicz.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) is a recombinant human glycoprotein that promotes proliferation and differentiation of granulocytic-committed progenitors. It is commonly used to treat neutropenia and is generally well tolerated. Occurrences of rare but serious adverse events in association with the use of G-CSF have been described. We report the case of a 54-year-old male with squamous cell carcinoma of the lung who developed abdominal aortitis following the use of G-CSF. Other possible aetiological conditions were excluded based on laboratory and radiological evaluations. To our knowledge, this represents the second case report demonstrating an association between aortitis and the use of G-CSF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19888788     DOI: 10.2165/11530790-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  10 in total

1.  Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma.

Authors:  Nicole J Watring; Thomas W Wagner; James J Stark
Journal:  Am J Emerg Med       Date:  2007-02       Impact factor: 2.469

2.  Vascular inflammation (vasculitis) in sweet syndrome: a clinicopathologic study of 28 biopsy specimens from 21 patients.

Authors:  Janine C Malone; Stephen P Slone; Lisa A Wills-Frank; Paul K Fearneyhough; Sheron C Lear; L Jane Goldsmith; Antoinette F Hood; Jeffrey P Callen
Journal:  Arch Dermatol       Date:  2002-03

Review 3.  The spectrum of chronic periaortitis.

Authors:  D V Parums
Journal:  Histopathology       Date:  1990-05       Impact factor: 5.087

4.  Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections.

Authors:  H H Euler; P Harten; R A Zeuner; U M Schwab
Journal:  J Rheumatol       Date:  1997-11       Impact factor: 4.666

5.  Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.

Authors:  Charles L Bennett; Andrew M Evens; Leslie A Andritsos; Lakshmi Balasubramanian; Mark Mai; Matthew J Fisher; Timothy M Kuzel; Cara Angelotta; June M McKoy; Julie M Vose; Philip J Bierman; David J Kuter; Steven M Trifilio; Steven M Devine; Martin S Tallman
Journal:  Br J Haematol       Date:  2006-10-19       Impact factor: 6.998

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 7.  Chronic periaortitis: a spectrum of diseases.

Authors:  Augusto Vaglio; Carlo Buzio
Journal:  Curr Opin Rheumatol       Date:  2005-01       Impact factor: 5.006

Review 8.  Non-aneurysmal infectious aortitis: a case report.

Authors:  Aneesh T Narang; Niels K Rathlev
Journal:  J Emerg Med       Date:  2007-03-26       Impact factor: 1.484

9.  Diagnosis and follow up of aortitis in the elderly.

Authors:  A K Scheel; J Meller; R Vosshenrich; E Kohlhoff; U Siefker; G A Müller; F Strutz
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

10.  [Aortitis after G-CSF injections].

Authors:  C Darie; S Boutalba; P Fichter; J-F Huret; P Jaillot; F Deplus; S Gerenton; T Zenone; J-L Moreau; A Grand
Journal:  Rev Med Interne       Date:  2004-03       Impact factor: 0.728

  10 in total
  5 in total

1.  Carotidynia after anticancer chemotherapy.

Authors:  Shinichi Hayashi; Shuichiro Maruoka; Noriaki Takahashi; Shu Hashimoto
Journal:  Singapore Med J       Date:  2014-09       Impact factor: 1.858

2.  Aortitis and aortic dissection after administration of pegfilgrastim during adjuvant chemotherapy for early breast cancer.

Authors:  Eriko Shiraki; Mai Hamada-Nishimoto; Yookija Kang; Shigeru Tsuyuki
Journal:  Int Cancer Conf J       Date:  2022-02-23

3.  Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF).

Authors:  Edward B Miller; Roy Grosu; Zvi Landau
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

4.  Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review.

Authors:  Kirsi Taimen; Samu Heino; Ia Kohonen; Heikki Relas; Riikka Huovinen; Arno Hänninen; Laura Pirilä
Journal:  Rheumatol Adv Pract       Date:  2020-02-06

Review 5.  Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.

Authors:  Hideko Hoshina; Hiroyuki Takei
Journal:  BMC Cancer       Date:  2019-12-16       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.